title: A report from the 22nd Congress of the European Academy of Dermatology and Venereology (October 2-6, 2013 - Istanbul, Turkey).
abstract: During the annual congress of the European Academy of Dermatology and Venereology (EADV), Istanbul, a bridge across Europe and Asia, attracted dermatologists from both continents, along with researchers and clinicians from the Americas and other parts of the world, to discuss new advancements in the treatment of common, in many cases severe, diseases that affect not only the skin, but also deep into human bodies. The following report reflects the important fact in dermatology that biologic and targeted therapies are conquering the drug armamentarium well beyond the known area of psoriasis and melanoma into areas such as atopic dermatitis. In fact, early clinical trials with two novel monoclonal antibodies presented during the first day of scientific sessions at EADV demonstrated a favorable efficacy profile that anticipates innovative developments in the strategies for treating atopic dermatitis and possibly other diseases of the skin. Many other topics of interest were also discussed during the meeting's sessions and electronic poster presentations, as summarized in the report.
authors.affiliation: Thomson Reuters, Barcelona, Spain. xavier.rabasseda@thomsonreuters.com.
authors.forename: X
authors.initials: X
authors.lastname: Rabasseda
mesh_terms: D003876:Dermatitis, Atopic / Q000188:drug therapy; D006801:Humans; D008545:Melanoma / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy
keywords: Actinic keratosis; Atopic dermatitis; Dermatology; Nonmelanoma skin cancer; Psoriasis; Skin and skin structure infections